Protelos safety update

The MHRA has issued advice stating that women taking the postmenopausal osteoporosis drug strontium ranelate (Protelos) should be alert to the risk of severe allergic reactions.

If patients develop a rash they should stop taking the drug and consult their doctor immediately. Once treatment has been stopped it should not be re-introduced.

The MHRA advice follows a European Medicines Agency (EMEA) recommendation that the product information for Protelos should be changed to include warnings on severe hypersensitivity syndromes as an urgent measure.


Up to 16 November 2007, the EMEA had received 16 reports of ‘drug rash with eosinophilia and systemic symptoms (DRESS)’ in patients treated with Protelos/Osseor (brand name in some other countries), two of which were fatal.

 

Further information: MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Inhaler prescribing guidance issued as spike in demand causes shortages

Inhaler prescribing guidance issued as spike in demand causes shortages

Prescribers have been urged not to extend repeat prescription...

Free coronavirus news and resources on MIMS, MIMS Learning and GPonline

Free coronavirus news and resources on MIMS, MIMS Learning and GPonline

As the coronavirus crisis continues, we at Haymarket...

Transdermal estradiol spray offers new treatment option for HRT

Transdermal estradiol spray offers new treatment option for HRT

Lenzetto (estradiol) is the first transdermal spray...